

Peer review comments – Doxycycline

Managing COVID-19 rapid guideline (NG191)

Peer review organisations

For a list of stakeholders invited to comment on COVID-19 guidance as part of the targeted peer review, please see the [targeted peer review stakeholder list](#) on the NICE website.

Overarching category	Guideline section	Theme of comments	Action taken
General comments	Recommendation	All peer reviewers agreed with the recommendation or had no comments.	No action necessary
Secondary care	Recommendation	One peer reviewer queried whether secondary care should also be referred to in this recommendation, stating that they considered it would also be applicable to this setting. They noted that there was no data in this population, but an assumption could be made based on community data.	The appropriate setting for the recommendation had been discussed by the expert panel. They noted that there was no evidence for hospitalised patients, and they preferred not to extrapolate to other settings, as the included evidence was specific to the community. No action necessary
Children	Evidence summary	It was noted by one peer reviewer that this recommendation is based on adult data but that the recommendation not to use doxycycline would make it likely that it would not be used in children. It was also commented that the recommendation would not change practice or lead to differences in care between adults and children.	No action necessary
Study design	Evidence to decision	One peer reviewer made comments on the open label design of this study, noting i) potential unspecified ethical issues, and ii) that an open label design may not be appropriate for some patient reported outcomes.	The open label design of the study was considered in the risk of bias assessment for this study. No action necessary

Date of completion: 30/06/2021